In our patients with hematologic malignancies, after treatment with RTX/ibrutinib and teclistamab, 91.0% showed hypo-γ-globulinemia, 84.7% had low levels of IgG, and 72.3% had low levels of CD19. This evidence concerns the gene CD19 and hematologic disorder.